ES2352739T3
(en)
*
|
1997-11-21 |
2011-02-22 |
Purdue Neuroscience Company |
2-SUBSTITUTED AMINO ACETAMIDS AND THE USE OF THE SAME.
|
EP1277754B8
(en)
*
|
2000-04-27 |
2005-09-28 |
Astellas Pharma Inc. |
Imidazopyridine derivatives
|
DE10117184A1
(en)
*
|
2001-04-05 |
2002-10-17 |
Gruenenthal Gmbh |
Substituted imidazole [1,2-a] pyridin-3-yl amide and amine compounds
|
PL366827A1
(en)
|
2001-06-21 |
2005-02-07 |
Smithkline Beecham Corporation |
Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
|
IL159811A0
(en)
*
|
2001-07-13 |
2004-06-20 |
Neurogen Corp |
Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
|
WO2003031446A1
(en)
|
2001-10-05 |
2003-04-17 |
Smithkline Beecham Corporation |
Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
|
WO2003050120A1
(en)
|
2001-12-11 |
2003-06-19 |
Smithkline Beecham Corporation |
Pyrazolo-pyridine derivatives as antiherpes agents
|
JP2005525382A
(en)
|
2002-03-07 |
2005-08-25 |
スミスクライン ビーチャム コーポレーション |
Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing the same
|
MXPA04010288A
(en)
|
2002-04-19 |
2005-05-17 |
Cellular Genomics Inc |
IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF.
|
JP2005529919A
(en)
|
2002-05-10 |
2005-10-06 |
スミスクライン ビーチャム コーポレーション |
Therapeutic compounds
|
WO2004022562A1
(en)
|
2002-09-09 |
2004-03-18 |
Cellular Genomics, Inc. |
6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
|
MXPA05003058A
(en)
|
2002-09-19 |
2005-05-27 |
Schering Corp |
Imidazopyridines as cyclin dependent kinase inhibitors.
|
DE10246890A1
(en)
*
|
2002-10-08 |
2004-04-22 |
Grünenthal GmbH |
New C-(imidazo-(1,2-a)-pyridin-3-yl)-methylamines, are nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, septic shock, neurodegenerative diseases, inflammatory pain or cancer
|
WO2004072081A1
(en)
|
2003-02-10 |
2004-08-26 |
Cellular Genomics, Inc. |
Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
US7259164B2
(en)
|
2003-08-11 |
2007-08-21 |
Cgi Pharmaceuticals, Inc. |
Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
|
JP5206405B2
(en)
*
|
2005-03-21 |
2013-06-12 |
エムイーアイ・ファーマ・インコーポレイテッド |
Imidazo [1,2-a] pyridine derivatives: production and pharmaceutical use
|
WO2007024294A2
(en)
|
2005-05-03 |
2007-03-01 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
TW200800213A
(en)
|
2005-09-02 |
2008-01-01 |
Abbott Lab |
Novel imidazo based heterocycles
|
AR061229A1
(en)
|
2006-06-06 |
2008-08-13 |
Schering Corp |
IMIDAZOPIRAZINS AS INHIBITORS OF PROTEIN QUINASA
|
AR064491A1
(en)
|
2006-12-22 |
2009-04-08 |
Astex Therapeutics Ltd |
IMIDAZO DERIVATIVES [1, 2-A] PYRIMIDINE, A PROCESS FOR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY FGFR KINASES.
|
MX2009006704A
(en)
|
2006-12-22 |
2009-06-30 |
Astex Therapeutics Ltd |
New compounds.
|
GB0720038D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New compounds
|
GB0720041D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New Compounds
|
AU2009215191A1
(en)
|
2008-02-13 |
2009-08-20 |
Gilead Connecticut, Inc. |
6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
|
WO2009132238A2
(en)
|
2008-04-24 |
2009-10-29 |
Newlink Genetics |
Ido inhibitors
|
CN102112475A
(en)
*
|
2008-05-29 |
2011-06-29 |
西特里斯药业公司 |
Imidazopyridine and related analogs as sirtuin modulators
|
GB0810902D0
(en)
|
2008-06-13 |
2008-07-23 |
Astex Therapeutics Ltd |
New compounds
|
AU2009325133B2
(en)
|
2008-12-08 |
2016-02-04 |
Gilead Connecticut, Inc. |
Imidazopyrazine Syk inhibitors
|
BRPI0922225B1
(en)
|
2008-12-08 |
2022-01-11 |
Gilead Connecticut, Inc. |
SYK IMIDAZOPYRAZINE INHIBITORS, PHARMACEUTICAL COMPOSITION, AND COMPOUND USE
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
GB0906472D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
GB0906470D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
CN102596961B
(en)
|
2009-10-30 |
2015-12-02 |
詹森药业有限公司 |
Imidazo [1,2-b] pyridazine derivatives and the purposes as PDE10 inhibitor thereof
|
AR080754A1
(en)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
|
CN103168039B
(en)
|
2010-03-11 |
2016-08-03 |
吉利德康涅狄格公司 |
Imidazopyridine syk inhibitor
|
US9173887B2
(en)
|
2010-12-22 |
2015-11-03 |
Abbvie Inc. |
Hepatitis C inhibitors and uses thereof
|
ES2575092T3
(en)
|
2011-06-27 |
2016-06-24 |
Janssen Pharmaceutica, N.V. |
1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline derivatives
|
DE102012200349A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
Substituted fused pyrimidines and triazines and their use
|
EP2863909B1
(en)
|
2012-06-26 |
2020-11-04 |
Janssen Pharmaceutica N.V. |
Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
|
EP2869822B1
(en)
|
2012-07-09 |
2016-09-14 |
Janssen Pharmaceutica, N.V. |
Inhibitors of phosphodiesterase 10 enzyme
|
US8796305B2
(en)
|
2012-11-05 |
2014-08-05 |
Bayer Pharma Aktiengesellschaft |
Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9126998B2
(en)
|
2012-11-05 |
2015-09-08 |
Bayer Pharma AG |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9624214B2
(en)
|
2012-11-05 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US8778964B2
(en)
|
2012-11-05 |
2014-07-15 |
Bayer Pharma Aktiengesellschaft |
Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
|
PL2925757T3
(en)
|
2012-11-19 |
2018-06-29 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
US9243001B2
(en)
*
|
2013-03-15 |
2016-01-26 |
Epizyme, Inc. |
Substituted benzene compounds
|
US20160031907A1
(en)
*
|
2013-03-15 |
2016-02-04 |
Epizyme, Inc. |
Substituted Benzene Compounds
|
ES2625744T3
(en)
|
2013-06-04 |
2017-07-20 |
Bayer Pharma Aktiengesellschaft |
Imidazo [1,2-a] pyridines substituted with 3-aryl and their use
|
KR20160030541A
(en)
|
2013-07-10 |
2016-03-18 |
바이엘 파마 악티엔게젤샤프트 |
Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
|
MX2016001480A
(en)
|
2013-07-30 |
2017-01-05 |
Gilead Connecticut Inc |
Formulation of syk inhibitors.
|
PT3027618T
(en)
|
2013-07-30 |
2020-10-12 |
Kronos Bio Inc |
Polymorph of syk inhibitors
|
US9687492B2
(en)
|
2013-12-04 |
2017-06-27 |
Gilead Sciences, Inc. |
Methods for treating cancers
|
TWI662037B
(en)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
Syk inhibitors
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
EP3107920B1
(en)
|
2014-02-19 |
2017-10-18 |
Bayer Pharma Aktiengesellschaft |
3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
|
WO2015140199A1
(en)
|
2014-03-21 |
2015-09-24 |
Bayer Pharma Aktiengesellschaft |
Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
CA2947374A1
(en)
|
2014-05-02 |
2015-11-05 |
Bayer Pharma Aktiengesellschaft |
Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
|
JP6310144B2
(en)
|
2014-07-14 |
2018-04-18 |
ギリアード サイエンシーズ, インコーポレイテッド |
Combinations for treating cancer
|
US10174021B2
(en)
|
2014-12-02 |
2019-01-08 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrazolo[1,5-A]pyridines and their use
|
EP3227287B1
(en)
|
2014-12-02 |
2019-08-07 |
Bayer Pharma Aktiengesellschaft |
Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
|
JP2018505885A
(en)
|
2015-02-05 |
2018-03-01 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Substituted pyrazolo [1,5-a] -pyridine-3-carboxamide and uses thereof
|
JP2018505886A
(en)
|
2015-02-05 |
2018-03-01 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
N-substituted 8-[(2,6-difluorobenzyl) oxy] -2,6-dimethylimidazo [1,2-a] as a stimulant of soluble guanylate cyclase (SGC) for treating cardiovascular disease Pyrazine-3-carboxamide derivatives
|
WO2016161572A1
(en)
*
|
2015-04-08 |
2016-10-13 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
WO2018184976A1
(en)
|
2017-04-05 |
2018-10-11 |
Bayer Pharma Aktiengesellschaft |
Substituted imidazo[1,2-a]pyridinecarboxamides and use of same
|
EP3672974A1
(en)
|
2017-08-25 |
2020-07-01 |
Gilead Sciences, Inc. |
Polymorphs of syk inhibitors
|
CA3130848A1
(en)
|
2019-02-22 |
2020-08-27 |
Kronos Bio, Inc. |
Solid forms of condensed pyrazines as syk inhibitors
|
US11718622B2
(en)
|
2020-03-16 |
2023-08-08 |
Exelixis Inc. |
Heterocyclic adenosine receptor antagonists
|